<img alt="" src="https://secure.wake4tidy.com/244317.png" style="display:none;">
2017-11-06

Vironova a proud sponsor of the very first Swedish Symposium on Deep Learning

On 20-21 June, the first Swedish Symposium on Deep Learning will take place in Stockholm. Deep learning is a field of machine learning that builds on complex neural networks – originally used to mimic networks of neurons in the brain. In Vironova’s...

2017-11-06

Great success at the Bioprocess International EU Summit in Amsterdam!

A satisfied and happy Vironova team returned from the BPI trade show in Amsterdam last week. Many visitors came to watch a MiniTEM demo in our beautiful booth and an appreciative and enthusiastic crowd enjoyed the presentation “Automated...

2017-11-06

Meaningful insights from the sub-visible space

Don’t miss our talk at BPI European Summit: Automated characterization of gene therapy vectors, VLPs and whole viruses. By Josefina Nilsson, head of EM services. April 25, at 15.00 in the vaccine manufacturing stream. A case study how integrity and...

2017-11-06

Dr Josefina Nilsson, Head of EM services at Vironova shares her thoughts on sub-visible particle characterization

Josefina has extensive experience of characterization of nano-scaled sub-visible particles as a service provider since ten years to the biopharmaceutical industry, from early development to final manufacturing.

2017-11-06

Webinar April 6 - Interview with Vironova founder and CEO Mohammed Homman

Vironova will host a webinar “Automated purity and integrity check of gene therapy vectors” on April 6 at 3 pm CET. (Agenda and registration can be found here.)

2017-11-06

MiniTEM™ event in Leiden attracts key players within gene therapy and vaccine industries

A full-day event including live demo of MiniTEM and presentations showing how to go from manual to automated virus particle characterization attracted more than 10 different companies located in Europe. Invited speaker Vesa Turkki, Senior Scientist...

2017-11-06

Vironova is building a state of the art electron microscopy (EM) facility to meet increasing demand

Vironova has established a growing number of global customers in the highly-regulated and quality demanding pharmaceutical industry, who focus on drug/gene delivery and vaccine development. Currently 7 of the 10 largest biopharmaceutical companies...

2017-11-06

Vironova has filed a US provisional patent for analyzing viral vector content using cryoTEM

Vironova has now filed a patent for quantitative analysis of viral vector content using cryoTEM, a method that has already triggered plenty of interest amongst our customers.

2017-11-06

Free webinar April 6: Automated purity and integrity analysis of gene therapy vectors

Time: 3:00pm London, 10:00am New York

2017-11-06

Record turnover for NOW Electronics in its first year as a Vironova-owned company

2016 saw Mikael Wik appointed as new CEO and a record sales performance that beat all previous years, with a turnover of 25,9 MSEK. The two founders and previous leaders since 1985 continue to be active in sales and business development.